What question did this study set out to answer?

To assess the safety and efficacy of the combination of selinexor and mezigdomide in RRMM patients ineligible for T-cell therapies.

April 19, 2026HaematologicaOpen Access

P43 | Selinexor, Mezigdomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Who Relapsed or Are Ineligible for T-Cell–redirecting Therapy: Stomp Phase 1 Preliminary Results

View Full Paper

Ask AI

Bookmark

Authors

Phase 1 trial evaluates effectiveness in RRMM patients after T-cell therapy failure, suggesting potential benefits.

To assess the safety and efficacy of the combination of selinexor and mezigdomide in RRMM patients ineligible for T-cell therapies.
Evaluation of three dose cohorts: S 40 mg/M 0.6 mg, S 60 mg/M 0.6 mg, S 60 mg/M 1.0 mg
Prophylactic measures for nausea and thromboembolism
Assessment of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D)
No dose-limiting toxicities (DLTs) in cohorts 1 and 2; manageable DLTs in cohort 3
Overall response rate of 40% observed in patients with disease control
Increase in activated and proliferating T-cells with decrease in exhaustion markers

Mo et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark